stk-009
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05665062)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lupus Erythematosus, Systemic · Phase 1
- Lupus Nephritis · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Scleroderma, Systemic · Phase 1
Mechanism of action
- Interleukin-2AGONIST
IL2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06544330 | Phase 1 | Sep 30, 2024 | Synthekine |
| NCT05665062 | Phase 1 | Dec 31, 2022 | Synthekine |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Synthekine | For profit | 2 | 2 | 1 | 2022 |
1 organizations
Page 1 / 1